Amgen Inc. AMGN
414.61
8.57
2.11%
as of 25 Sep
- Market cap
- $219.1B
- P/E
- 25.6×
Follow AMGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Amgen Inc. (AMGN) Return on assets
Amgen Inc.'s return on assets over the twelve months to 30 June 2026 was 9.53%, up 1.1 percentage points from fiscal 2025 (8.45%). Over the past ten years it has ranged from 2.51% (fiscal 2017) to 12.4% (fiscal 2019); the current reading is higher than 36% of that period. That is above the Drug Manufacturers General industry median of 2.76% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 8.45% | 4.12 |
| FY2024 | 4.33% | (3.95) |
| FY2023 | 8.28% | (2.10) |
| FY2022 | 10.4% | 0.88 |
| FY2021 | 9.50% | (2.34) |
| FY2020 | 11.8% | (0.60) |
| FY2019 | 12.4% | 0.97 |
| FY2018 | 11.5% | 8.96 |
| FY2017 | 2.51% | (7.85) |
| FY2016 | 10.4% | 0.48 |
Against its own ten years
Low 2.51%
High 12.4%
Ten-year median
9.88%
Current reading's percentile
36
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| NVS Novartis AG compare | 11.3% |
| BMY Bristol Myers Squibb Company compare | 10.2% |
| AMGN Amgen Inc. | 9.53% |
| AZN AstraZeneca PLC compare | 9.15% |
| ABBV AbbVie Inc. compare | 4.61% |
| MRK Merck & Co., Inc. compare | 2.57% |
| PFE Pfizer Inc. compare | 2.13% |
| GILD Gilead Sciences, Inc. compare | −6.17% |
| Drug Manufacturers General industry median | 2.76% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on AMGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement